Provenge is an autologous cellular immunotherapy with the active ingredient sipuleucel-T, formulated as a suspension for intravenous infusion. It consists of autologous peripheral blood mononuclear cells activated with a recombinant human protein, PAP-GM-CSF. The product is intended to potentially direct an immune response against prostate cancer-associated antigens. Key components include antigen presenting cells and PAP-GM-CSF, suspended in Lactated Ringer's Injection, USP.